Skip to main content

Table 3 Most common any-grade (≥ 20% of patients) and grade 3/4 (≥ 10% of patients) TEAEs

From: Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Event, n (%) Daratumumab 16 mg/kg (n = 32)
Any grade Grade 3/4
Any TEAE 32 (100.0) 19 (59.4)
Pyrexia 21 (65.6) 4 (12.5)
Thrombocytopenia 9 (28.1) 8 (25.0)
Anemia 9 (28.1) 5 (15.6)
Increased alanine aminotransferase 9 (28.1) 1 (3.1)
Neutropenia 8 (25.0) 6 (18.8)
Headache 8 (25.0) 1 (3.1)
Increased aspartate aminotransferase 8 (25.0) 1 (3.1)
Chills 8 (25.0) 0
Leukopenia 7 (21.9) 5 (15.6)
Fatigue 7 (21.9) 1 (3.1)
  1. TEAE, treatment-emergent adverse event
\